
A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
Adding pembrolizumab to combination of trastuzumab and chemotherapy improved progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
Thanos Zomas, MD, global medical lead for lymphoma and leukemia and for the Adcetris Program, Takeda Oncology, discussed results of the ECHELON-1 trial.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.